The pandemic provided a reason to the stock market to be excited about the pharma sector that had been facing lacklustre prospects amid challenges in the US business, USFDA compliance issues, pricing pressure, big-bang acquisitions not working out on expected lines and modest growth in the domestic market.
BofA Securities initiates coverage on Groww with ‘buy’ rating; shares rally 4% to record high. Here’s what the brokerage said
Groww shares hit a new 52-week high. BofA Securities initiated coverage with a Buy rating. The brokerage sees strong growth potential for Groww. It expects
April 15, 2026